AC Immune (NASDAQ:ACIU) Given Consensus Recommendation of “Hold” by Analysts

AC Immune (NASDAQ:ACIU) has been given an average rating of “Hold” by the five ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.00.

Several research firms have recently issued reports on ACIU. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, March 16th. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Jefferies Financial Group reissued a “buy” rating and issued a $7.00 price objective on shares of AC Immune in a research report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st.

AC Immune Stock Down 2.2%

NASDAQ:ACIU opened at $2.70 on Tuesday. The company has a market cap of $274.78 million, a P/E ratio of -3.21 and a beta of 1.63. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $4.00. The firm’s 50 day moving average is $2.94 and its two-hundred day moving average is $3.10.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%. The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.14 million. Research analysts forecast that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its holdings in AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in AC Immune by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after purchasing an additional 36,353 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in AC Immune during the 3rd quarter valued at $549,000. Marshall Wace LLP acquired a new stake in AC Immune during the 4th quarter valued at $586,000. Finally, Sei Investments Co. acquired a new stake in AC Immune during the 2nd quarter valued at $51,000. 51.36% of the stock is owned by institutional investors and hedge funds.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.